Plasma Substance-P in Neuroendocrine Tumors and Idiopathic Flushing: The Value of Pentagastrin Stimulation Tests and the Effects of Somatostatin Analog*
- 1 June 1990
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 70 (6) , 1702-1709
- https://doi.org/10.1210/jcem-70-6-1702
Abstract
We examined the role of the potent vasoactive kinin substance-P (SP) in flushing derived from various causes. SP was measured in plasma after acetone/ether extraction using an antiserum directed at the carboxy-terminal 5-11 amino acid region of undecapeptide SP. The antiserum had less than 1% cross-reaction with the other neurokinins, neurokinin-A and neuropeptide-K, that derive from the .beta.-preprotachykinin gene and share carboxy-terminal residues. Basal and pentagastrin-stimulated SP levels were measured in 22 healthy controls, 11 patients with histologically proven carcinoid tumors, 8 patients with tumors other than carcinoid, and 7 patients with idiopathic flushing (IF). Basal SP levels were less than 10 pg/mL in normal subjects. All patients with midgut carcinoid tumors had SP levels greater than 25 pg/mL, as did 7 of 8 patients with noncarcinoid tumor and 5 of 7 patients with IF. Using 50 pg/mL as the cutoff point, the sensitivity was 63% for detection of a tumor, and 100% of nontumor patients were excluded. Pentagastrin administration uniformly induced flushing and caused a rise in SP levels greater than 150 pg/mL in 5 of 10 patient with carcinoid tumors, 3 of 8 with noncarcinoid tumors, and 0 and 7 with IF, i.e. a SP rise of more than 100 pg/mL suggests a tumor. Administration of somatostatin (150 .mu.g) 0.5 h before the pentagastrin abolished flushing in all carcinoid patients and reduced SP levels, but not into the normal range. Long-term treatment with SMS significantly reduced flushing and lowered SP levels, but did not restore these to normal. We conclude that 90% of patients with carcinoid/noncarcinoid tumor have raised COOH-terminal SP levels. A basal level above 50 pg/mL or a pentagastrin-stimulated rise of more than 100 pg/mL distinguishes carcinoid from IF. The dissociation between SP concentrations and flushing suggests that SP may not be the only kinin involved in the flushing associated with carcinoid tumors.This publication has 9 references indexed in Scilit:
- Effect of a long-acting somatostatin analogue (octreotide) on circulating tachykinins and the pentagastrin-induced carcinoid flushEuropean Journal of Clinical Pharmacology, 1989
- Distinguishing features of idiopathic flushing and carcinoid syndromeArchives of internal medicine (1960), 1988
- SOMATOSTATIN ANALOG (SMS-201-995) IN PATIENTS WITH GASTRINOMAS1988
- Response of Thyrotropin-Secreting Pituitary Adenomas to a Long-Acting Somatostatin AnalogueNew England Journal of Medicine, 1987
- Circulating Tachykinins (Substance P, Neurokinin A, Neuropeptide K) and the Carcinoid FlushScandinavian Journal of Gastroenterology, 1987
- THE PENTAGASTRIN TEST IN THE DIAGNOSIS OF THE CARCINOID-SYNDROME - BLOCKADE OF GASTROINTESTINAL SYMPTOMS BY KETANSERIN1985
- The Effect of Carcinoid Levels of Serotonin and Substance P on HemodynamicsAnnals of Surgery, 1984
- Nucleotide sequences of cloned cDNAs for two types of bovine brain substance P precursorNature, 1983
- Substance P in an argentaffin carcinoid of the caecum: Biochemical and biological characterizationVirchows Archiv, 1981